DK2968461T3 - Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf - Google Patents
Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf Download PDFInfo
- Publication number
- DK2968461T3 DK2968461T3 DK14722439.8T DK14722439T DK2968461T3 DK 2968461 T3 DK2968461 T3 DK 2968461T3 DK 14722439 T DK14722439 T DK 14722439T DK 2968461 T3 DK2968461 T3 DK 2968461T3
- Authority
- DK
- Denmark
- Prior art keywords
- pdgf
- methods
- fusion proteins
- binding portions
- vegf binding
- Prior art date
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780914P | 2013-03-13 | 2013-03-13 | |
PCT/US2014/026872 WO2014160507A1 (en) | 2013-03-13 | 2014-03-13 | Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2968461T3 true DK2968461T3 (da) | 2022-12-19 |
Family
ID=50680144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14722439.8T DK2968461T3 (da) | 2013-03-13 | 2014-03-13 | Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf |
Country Status (27)
Country | Link |
---|---|
US (4) | US9637534B2 (da) |
EP (1) | EP2968461B1 (da) |
JP (2) | JP6561042B2 (da) |
KR (1) | KR102228921B1 (da) |
CN (1) | CN105188733B (da) |
AR (1) | AR095437A1 (da) |
AU (2) | AU2014243712B2 (da) |
BR (1) | BR112015022208A8 (da) |
CA (1) | CA2904623A1 (da) |
DK (1) | DK2968461T3 (da) |
ES (1) | ES2933558T3 (da) |
FI (1) | FI2968461T3 (da) |
HK (1) | HK1220618A1 (da) |
HR (1) | HRP20221447T1 (da) |
HU (1) | HUE060464T2 (da) |
IL (2) | IL240950B (da) |
LT (1) | LT2968461T (da) |
MX (1) | MX363533B (da) |
PL (1) | PL2968461T3 (da) |
PT (1) | PT2968461T (da) |
RS (1) | RS63820B1 (da) |
RU (1) | RU2692652C2 (da) |
SG (3) | SG10201707501TA (da) |
SI (1) | SI2968461T1 (da) |
TW (1) | TWI631133B (da) |
UY (1) | UY35407A (da) |
WO (1) | WO2014160507A1 (da) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
DK2968461T3 (da) | 2013-03-13 | 2022-12-19 | Genzyme Corp | Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf |
US20160137717A1 (en) * | 2013-06-20 | 2016-05-19 | Gabriela Burian | Use of a vegf antagonist in treating choroidal neovascularisation |
SI3041513T1 (sl) | 2013-09-08 | 2020-11-30 | Kodiak Sciences Inc. | Zwitterionski polimerni konjugati faktorja VIII |
KR101819135B1 (ko) | 2014-03-18 | 2018-01-18 | 한국과학기술원 | 당화 vegf 디코이 수용체 융합 단백질 |
AU2015279560B2 (en) * | 2014-06-28 | 2020-09-17 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
MX2017008643A (es) * | 2015-03-11 | 2018-04-26 | Allgenesis Biotherapeutics Inc | Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf). |
BR112017027567A2 (pt) * | 2015-06-28 | 2018-09-04 | Allgenesis Biotherapeutics Inc. | proteínas de fusão para inibir a angiogênese |
WO2017084616A1 (en) * | 2015-11-19 | 2017-05-26 | Zhuhai Tairuishang Biopharm Ltd. | Methods and compositions for binding vegf |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
EP3436484A4 (en) | 2016-03-30 | 2019-12-04 | AB Biosciences, Inc. | RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND METHODS OF MAKING AND USING THEM |
KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
JP6849390B2 (ja) * | 2016-10-28 | 2021-03-24 | 花王株式会社 | 関節のこわばり改善剤 |
WO2019083171A2 (ko) * | 2017-10-26 | 2019-05-02 | 주식회사 큐로진생명과학 | 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물 |
KR102205830B1 (ko) * | 2017-10-26 | 2021-01-21 | 주식회사 큐로진생명과학 | 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물 |
CN111406071B (zh) * | 2017-11-16 | 2024-01-16 | 成都硕德药业有限公司 | Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途 |
US11548931B2 (en) | 2017-11-16 | 2023-01-10 | Xl-Protein Gmbh | PASylated VEGFR/PDGFR fusion proteins and their use in therapy |
WO2019147944A1 (en) * | 2018-01-26 | 2019-08-01 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disordres using anti-vegf agents |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
CN114867487A (zh) | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
US20230024569A1 (en) * | 2019-12-04 | 2023-01-26 | Cdmogen Co., Ltd. | Composition for treating diabetic retinopathy, comprising raav containing soluble vegfr-1 variant cdna |
CN111826400A (zh) * | 2020-07-21 | 2020-10-27 | 中科宝承生物医学科技有限公司 | 一种双特异性抗体nk细胞制备方法及其细胞和应用 |
CN112961250B (zh) * | 2021-03-01 | 2023-06-06 | 长春金赛药业有限责任公司 | 抗体融合蛋白及其应用 |
CN113105558A (zh) * | 2021-04-01 | 2021-07-13 | 芜湖英特菲尔生物制品产业研究院有限公司 | 一种酿酒酵母表达人rPDGF-HSA融合蛋白及其标准品的制备方法 |
JP2024525186A (ja) * | 2021-06-18 | 2024-07-10 | イカロベック リミテッド | 網膜障害 |
WO2023199951A1 (ja) * | 2022-04-13 | 2023-10-19 | 株式会社セルージョン | 抗vegf機能を有する多能性幹細胞及びその分化細胞 |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
KR20240019034A (ko) * | 2022-08-02 | 2024-02-14 | 주식회사 파노로스바이오사이언스 | 변형된 융합 단백질 및 이의 용도 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4454151A (en) | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US4952515A (en) | 1987-05-22 | 1990-08-28 | Polymer Technology International Corp. | Method of detection using a test strip having a non particulate dialyzed polymer layer |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
AU1411092A (en) | 1991-01-31 | 1992-09-07 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
JP4860886B2 (ja) | 2000-06-01 | 2012-01-25 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 二本鎖パルボウイルスベクター |
US20030181531A1 (en) | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
WO2003077796A2 (en) | 2002-03-15 | 2003-09-25 | University Of Southern California | Ophthalmic solutions for delivery of expression vectors |
US20040058313A1 (en) | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
EP1804835B9 (en) | 2004-09-13 | 2010-09-29 | Genzyme Corporation | Multimeric constructs |
US7765583B2 (en) | 2005-02-28 | 2010-07-27 | France Telecom | System and method for managing virtual user domains |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
DE102005020510A1 (de) | 2005-04-29 | 2006-11-09 | Basf Ag | Verbundelement, insbesondere Fensterscheibe |
US8216575B2 (en) * | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
CN101951925A (zh) * | 2008-02-20 | 2011-01-19 | 建新公司 | 血管发生抑制 |
JP5425180B2 (ja) | 2008-03-27 | 2014-02-26 | ザイモジェネティクス, インコーポレイテッド | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
CN102311502B (zh) * | 2010-07-10 | 2013-12-25 | 成都康弘生物科技有限公司 | 一种抑制血管新生或生长的融合蛋白及其医疗应用 |
MX2013006216A (es) * | 2010-12-02 | 2013-10-17 | Neurotech Usa Inc | Lineas celulares que secretan andamios de anticuerpos anti-angionicos y receptores solubles y sus usos. |
PT2691417T (pt) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Variantes de fc de anticorpos |
CN102219859B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
DK2968461T3 (da) | 2013-03-13 | 2022-12-19 | Genzyme Corp | Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf |
-
2014
- 2014-03-13 DK DK14722439.8T patent/DK2968461T3/da active
- 2014-03-13 EP EP14722439.8A patent/EP2968461B1/en active Active
- 2014-03-13 RS RS20221155A patent/RS63820B1/sr unknown
- 2014-03-13 KR KR1020157027849A patent/KR102228921B1/ko active IP Right Grant
- 2014-03-13 FI FIEP14722439.8T patent/FI2968461T3/fi active
- 2014-03-13 AU AU2014243712A patent/AU2014243712B2/en active Active
- 2014-03-13 PL PL14722439.8T patent/PL2968461T3/pl unknown
- 2014-03-13 MX MX2015011951A patent/MX363533B/es unknown
- 2014-03-13 PT PT147224398T patent/PT2968461T/pt unknown
- 2014-03-13 HR HRP20221447TT patent/HRP20221447T1/hr unknown
- 2014-03-13 HU HUE14722439A patent/HUE060464T2/hu unknown
- 2014-03-13 AR ARP140100983A patent/AR095437A1/es unknown
- 2014-03-13 US US14/210,354 patent/US9637534B2/en active Active
- 2014-03-13 CA CA2904623A patent/CA2904623A1/en not_active Abandoned
- 2014-03-13 CN CN201480026585.2A patent/CN105188733B/zh active Active
- 2014-03-13 SI SI201432005T patent/SI2968461T1/sl unknown
- 2014-03-13 RU RU2015142999A patent/RU2692652C2/ru active
- 2014-03-13 SG SG10201707501TA patent/SG10201707501TA/en unknown
- 2014-03-13 LT LTEPPCT/US2014/026872T patent/LT2968461T/lt unknown
- 2014-03-13 JP JP2016502268A patent/JP6561042B2/ja active Active
- 2014-03-13 UY UY0001035407A patent/UY35407A/es not_active Application Discontinuation
- 2014-03-13 SG SG11201506802SA patent/SG11201506802SA/en unknown
- 2014-03-13 ES ES14722439T patent/ES2933558T3/es active Active
- 2014-03-13 SG SG10201912956YA patent/SG10201912956YA/en unknown
- 2014-03-13 BR BR112015022208A patent/BR112015022208A8/pt not_active IP Right Cessation
- 2014-03-13 TW TW103109211A patent/TWI631133B/zh not_active IP Right Cessation
- 2014-03-13 WO PCT/US2014/026872 patent/WO2014160507A1/en active Application Filing
-
2015
- 2015-08-31 IL IL240950A patent/IL240950B/en active IP Right Grant
-
2016
- 2016-07-20 HK HK16108675.7A patent/HK1220618A1/zh unknown
-
2017
- 2017-03-28 US US15/471,725 patent/US10183983B2/en active Active
-
2018
- 2018-11-20 US US16/197,194 patent/US11084864B2/en active Active
- 2018-12-12 AU AU2018278902A patent/AU2018278902A1/en not_active Abandoned
-
2019
- 2019-02-04 JP JP2019017599A patent/JP2019123711A/ja active Pending
- 2019-05-19 IL IL266715A patent/IL266715A/en unknown
-
2021
- 2021-07-02 US US17/367,027 patent/US20220064262A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2968461T3 (da) | Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf | |
DK3356413T3 (da) | Anti-tigit-antigenbindingsproteiner og fremgangsmåder til anvendelse deraf | |
DK3280727T3 (da) | Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf | |
DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
DK2999103T3 (da) | Konverter og fremgangsmåde til styring deraf | |
DK3292141T3 (da) | Fusionsproteiner | |
DK3275895T3 (da) | Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf | |
DK3017286T3 (da) | Fremgangsmåde, kit og system til billeddannelse af en blodprøve | |
DK3107938T3 (da) | Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf | |
DK3744835T3 (da) | Dna modificerende fusionsproteiner og metoder til anvendelse deraf | |
DK3581207T3 (da) | Fusionsproteiner omfattende hoxd12 og nemo-bindingsdomæne og anvendelse deraf | |
DK3019533T3 (da) | Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf | |
DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
DK2970464T3 (da) | Anti-lag-3-bindende proteiner | |
DK3079719T3 (da) | ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3113797T3 (da) | Antistoffer, anvendelser og fremgangsmåder | |
DK3083680T3 (da) | Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse | |
DK3697091T3 (da) | Billedafkodningsindretning, billedafkodningsfremgangsmåde og billedafkodningsprogram | |
DK3265123T3 (da) | Antistoffer, anvendelser og fremgangsmåder | |
DK3322734T3 (da) | Multivalente og multispecifikke DR5-bindende fusionsproteiner | |
DK2894818T3 (da) | Kontrolmetode i software-definerede netværk, styreanordning og processor | |
DK2983704T3 (da) | Fusionspolypeptider og vacciner | |
DK3271453T3 (da) | Glycosylerede lysosomale proteiner, fremgangsmåde til fremstilling og anvendelser | |
DK3380119T3 (da) | Fmdv- og e2-fusionsproteiner og anvendelser deraf | |
DK3060922T3 (da) | Fremgangsmåde og anordning til proteinfremstilling |